

## REMARKS

A new paragraph beginning at page 1, line 11 has been added in the specification. The new paragraph lists the documents to which priority is claimed for the instant application.

Further, amendments to the specification similar to those made in the parents of the present application have also been made. These changes are of formal nature and do not add new matter into the specification. For example, (1) original figures 1 and 2 have been amended to clearly identify the two separate sequences shown as "1A", "1B", and "2A" and "2B", respectively. Corresponding amendments have been made in the legends of Figures 1 and 2; (2) a substitute Figure 4 is submitted that contains an explanation of each symbol used in the schematic representation of the trks and their alternate splice forms and their domains; (3) the legend of Figure 4 has been amended to better describe Figure 4 by defining the meaning of the triangles, which represent optionally present peptide inserts. Additionally, various typographical errors in the specification have been corrected.

Support for these amendments are found in the specification at page 17, line 1 to page 18, line 8, where the trk domains are described, in the detailed description of the trk's and their alternate splicing forms at pages 97-103, in the Examples at page 98, lines 22-28, where the 6 amino acid peptide insert into trk A is described by means of its nucleic acid sequence, and in the description of the non-human trkB isoform at page 98, line 30 to page 99, line 11.

In order to ensure conformity with the Sequence Listing submitted concurrently herewith, amendments to the specification have been made to reflect the new SEQ ID Nos in this Sequence Listing. The Sequence Listing is believed to better organize the sequences than the original SEQ ID Nos. For the Examiner's convenience, a brief explanation of the SEQ ID NO change follows: SEQ ID NO: 1 remains the nucleic acid sequence for a full-length human trkB; however, SEQ ID NO:2 is now the translated amino acid sequence of SEQ ID NO:1. SEQ ID NO: 3 is a truncated human trkB nucleic acid sequence, and SEQ ID NO: 4 is its corresponding translated amino acid sequence, which finds support in Figure 1B and in the detailed description of this splice form in the specification. SEQ ID NO: 5 is a full-length human trkC nucleic acid sequence (originally SEQ ID NO: 2), and SEQ ID NO: 6 is its corresponding translated amino acid sequence, which is also supported in Figure 2A. SEQ ID NO: 7 is a truncated human trkC nucleic acid sequence, and SEQ ID NO: 8 is its corresponding amino acid sequence, which finds support in Figure 2B and in the detailed description of this splice form in the specification. SEQ ID NO:9 is a full-length

human trkA amino acid sequence, which is found in Figure 16. SEQ ID NOs: 10 through 35 are nucleic acid sequences for the oligonucleotides found in Table 1. SEQ ID NO: 36 is amino acid sequence ESTDNFILF, which is bracketed in Figure 2A. SEQ ID NO: 37 is amino acid sequence LFNPSGNDFCIWCE, which is also bracketed in Figure 2A. SEQ ID NO: 38 is the nucleic acid sequence TCTCCTCTCGCCGGTGG and SEQ ID NO: 39 is its corresponding translated 6 amino acid peptide Ser-Pro-Ser-Arg-Trp, which are supported at least at page 98, line 26. Finally, SEQ ID NO: 40 is the amino acid sequence FVLFHKIPLDG from Figure 1B, which is the trkB alternate C-terminal sequence, and SEQ ID NO: 41 is the amino acid sequence from Figure 2B which represents the trkC alternate C-terminal sequence.

Applicants respectfully request entry of these paragraphs for prosecution in this application.

Also, new claims 6-12 have been added and their entry is respectfully requested.

Support for the new claims can be found in the specification on following pages:

Claim Number	Phrase	Support
6	pathological conditions	at least at page 5, lines 26-32, and page 91, lines 6-20
7	malignancies	at least at page 5, lines 17-19, and page 91, line 11
8	overexpress	at least at page 5, lines 17-19, and page 10, lines 20-25
9	pancreas	at least page 91, line 9
10	aberrant sprouting in epilepsy	at least page 91, line 12
11	psychiatric disorder	at least page 91, lines 12-13
12	BDNF, NT-3 and NT-4/5	at least page 4, line 10


No new matter is introduced by way of the addition of new claims. Accordingly, the present claims are entitled to the priority date of March 18, 1994.

The Examiner is invited to contact the undersigned at (650) 324-7037.

The Commissioner is authorized to charge any fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No. 39766-0033CP2C2-C1 ).

Respectfully submitted,

Date: October 31, 2003

  
\_\_\_\_\_  
Daphne Reddy  
Reg. No. 53,507

**HELLER EHRMAN WHITE & McAULIFFE LLP**  
**Customer No. 25213**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 463867 v1  
10/30/03 1:35 PM (39766.0033)